Close
Novotech

Actylis Opens API Manufacturing Facility

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access the Media Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Related stories

Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026

Sun Pharmaceutical Industries has agreed to acquire Organon in...

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...
- Advertisement -

Actylis, a global manufacturer of raw materials and performance ingredients for the life sciences and specialty chemicals markets, has opened a new 30,000 square foot cGMP facility in Eugene, OR. The multi-million dollar construction commenced in February of 2021 and was completed in September of 2022, with commissioning and qualification completed at the end of January 2023.

โ€œToday we are delighted to announce that this purpose-built 30,000 square foot facility has commenced operations, allowing us to develop and manufacture GMP APIs and pharma intermediates from clinical trial to commercial volumes,โ€ said Gilles Cottier, CEO of Actylis. โ€œWe designed this facility specifically to enable us to develop and produce innovative APIs for our customers. We worked closely with architect firm BCA (Blaise Cacciola Architect) and Coffman Engineering to build a facility that has the most up-to-date technology and equipment available.โ€

Christine Bellmor, site director, elaborated on some of the specific capabilities of the site. โ€œWe are excited to have this state-of-the-art facility here in Eugene come online after such an intensive design and development process,โ€ she said. โ€œWe have 7 manufacturing suites and our clean rooms will be ISO Class 8 compliant by Q3. We have a number of different reactors to allow flexibility for a variety of chemistries. Commissioning and qualifications for clinical GMP were completed at the end of January this year and we already have our first projects completed and more are underway. The new facility is a 10-minute drive from our R&D facility which is critical for scaling and developing new processes for the plant. We are very proud of the site and look forward to welcoming customers to the facility so that they can see for themselves the capabilities we offer.โ€

The Eugene facility is the latest GMP manufacturing facility that Actylis has commissioned. Along with the other GMP sites in Montreal (Canada), Limerick (Ireland) and Ahmedabad (India), Actylis has a presence in 10 countries spanning three continents and offers more than 4,500 products. Actylisโ€™ capabilities encompass the entire R&D, product development and manufacturing spectrum, including technical sales support, R&D, manufacturing and production, quality, supply chain, global sourcing, and regulatory compliance.

Latest stories

Related stories

Sun Pharma Organon Buyout Marks Largest Biopharma Deal 2026

Sun Pharmaceutical Industries has agreed to acquire Organon in...

How Mobile Field Hospitals Are Changing Emergency Care

Healthcare systems can collapse overnight, particularly in natural disasters...

How Automation Is Transforming Mail-Order Pharmacy Operations: Efficiency, Accuracy and ROI

This article includes: Expanding the Role of Mail-Order Pharmacies ...

Designing Biotech Financial Models for Series B Success

Building a compelling Series B case in biopharma goes well beyond efficacy data and market size projections. Sophisticated investors are increasingly focused on CMC risk, licensing obligations, and the defensibility of your manufacturing timeline. This article breaks down what the financial model behind a strong Series B actually looks like and what quietly kills deals that should have worked.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

โ€“ Access theMedia Pack Now

โ€“ Book a Conference Call

โ€“ Leave Message for Us to Get Back

Translate ยป